{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:29:04Z","timestamp":1777858144559,"version":"3.51.4"},"reference-count":77,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2014,11,11]],"date-time":"2014-11-11T00:00:00Z","timestamp":1415664000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:p>The United Kingdom Drug Strategy emphasises recovery as a key focus in the treatment of drug dependence. A framework for recovery is defined in the Recovery-Orientated Drug Treatment report, written by an expert working group, and comprises four key phases: engagement and stabilisation, including the establishment of treatment goals; preparation for change, involving engagement in psychosocial and pharmacological interventions; active change, including detoxification and medical withdrawal; and completion, including interventions that strengthen community integration. A body of evidence supports the benefits of buprenorphine, a partial agonist at mu opioid receptors, in supporting individualised recovery based on this framework, specifically in relation to the potential for rapid stabilisation, flexibility to transition to other treatment options or achieve abstinence, effective blocking of on-top use of illicit drugs, the treatment of comorbidities through the minimisation of drug\u2013drug interactions, and a good safety profile. In addition, the newer abuse-deterrent formulation of buprenorphine combined with the opioid antagonist naloxone is likely to strengthen recovery-orientated systems of care due to its potential to reduce misuse and diversion. Progress through the recovery journey and the ability to sustain recovery will depend on individual needs and goals and on the amount of recovery capital that individuals have developed.<\/jats:p>","DOI":"10.1177\/0269881114555248","type":"journal-article","created":{"date-parts":[[2014,11,12]],"date-time":"2014-11-12T00:43:43Z","timestamp":1415753023000},"page":"43-49","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Considerations on the role of buprenorphine in recovery from heroin addiction from a UK perspective"],"prefix":"10.1177","volume":"29","author":[{"given":"David J","family":"Nutt","sequence":"first","affiliation":[{"name":"Imperial College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2014,11,11]]},"reference":[{"key":"bibr1-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2006.09.012"},{"key":"bibr2-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(00)00141-1"},{"issue":"3","key":"bibr3-0269881114555248","first-page":"9","volume":"12","author":"Bacha J","year":"2010","journal-title":"Heroin Addict Relat Clin Probl"},{"key":"bibr4-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2009.02627.x"},{"key":"bibr5-0269881114555248","unstructured":"Best D, Rome A, Hanning KA, (2010) Research For Recovery: A Review of the Drugs Evidence Base. www.scotland.gov.uk. Available at: www.scotland.gov.uk\/socialresearch (accessed 5 Sep 2013)."},{"key":"bibr6-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/57.2.192"},{"key":"bibr7-0269881114555248","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1999.tb127675.x"},{"key":"bibr8-0269881114555248","unstructured":"Center for Substance Abuse Treatment (2005) Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. Treatment Improvement Protocol (TIP) Series, No. 43. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK64151\/. Available at: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK64151\/ (accessed 22 Aug 2012)."},{"key":"bibr9-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1080\/713659381"},{"key":"bibr10-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-11-90"},{"key":"bibr11-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(03)00058-9"},{"key":"bibr12-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1002\/hup.630"},{"issue":"133","key":"bibr13-0269881114555248","first-page":"3","author":"Cowan A","year":"2003","journal-title":"Int J Clin Pract Suppl"},{"key":"bibr14-0269881114555248","unstructured":"Cox BM, Borsodi A, Cal\u00f3 G, (2009) Opioid receptors, introductory chapter. http:\/\/www.iuphar-db.org 13\u201310\u20132009. Available at: http:\/\/www.iuphar-db.org\/DATABASE\/FamilyIntroductionForward?familyId=50 (accessed 3 Sep 2013)."},{"issue":"8","key":"bibr15-0269881114555248","first-page":"871","volume":"15","author":"Curcio F","year":"2011","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"4","key":"bibr16-0269881114555248","first-page":"23","volume":"14","author":"Dale-Perera A","year":"2012","journal-title":"Heroin Addict Relat Clin Probl"},{"key":"bibr17-0269881114555248","unstructured":"Department of Health (England) and the devolved administrations (2007) Drug Misuse and Dependence: UK Guidelines on Clinical Management. www.nta.nhs.uk 2007. Available at: www.nta.nhs.uk\/publications (accessed 26 Oct 2012)."},{"issue":"1","key":"bibr18-0269881114555248","first-page":"7","volume":"7","author":"Doran C","year":"2005","journal-title":"Heroin Addict Relat Clin Probl"},{"key":"bibr19-0269881114555248","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241140-00003"},{"key":"bibr20-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2011.642758"},{"key":"bibr21-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1038\/bjp.2008.51"},{"key":"bibr22-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2012.07.005."},{"key":"bibr23-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.1999.94913376.x"},{"key":"bibr24-0269881114555248","unstructured":"Ford C, Halliday K, Lawson E, (2011) Guidance for the use of substitute prescribing in the treatment of opioid dependence in primary care. www.rcgp.org.uk and www.smmgp.org.uk. Available at: www.smmgp.org.uk\/download\/guidance\/guidance004.pdf (accessed 5 Feb 2013)."},{"key":"bibr25-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022164"},{"key":"bibr26-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1100\/tsw.2005.52"},{"key":"bibr27-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2003.00352.x"},{"key":"bibr28-0269881114555248","first-page":"CD002025","volume":"3","author":"Gowing L","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr29-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-006-0258-x"},{"key":"bibr30-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-010-0048-2"},{"issue":"5","key":"bibr31-0269881114555248","first-page":"423","volume":"67","author":"Hagan H","year":"2000","journal-title":"Mt Sinai J Med"},{"key":"bibr32-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(00)00126-5"},{"key":"bibr33-0269881114555248","unstructured":"HM Government (2010) Drug strategy 2010: Reducing demand, restricting supply, building recovery: Supporting people to live a drug free life. www.homeoffice.gov.uk 2010. Available at: www.homeoffice.gov.uk\/drugs\/drug-strategy-2010\/ (accessed 15 Mar 2012)."},{"key":"bibr34-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011023431802"},{"key":"bibr35-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2005.03.006"},{"key":"bibr36-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25653"},{"key":"bibr37-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2011.04.002"},{"key":"bibr38-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1080\/10826080802714462"},{"key":"bibr39-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1080\/13556219772732"},{"key":"bibr40-0269881114555248","unstructured":"Leavitt SB (2003) Methadone Dosing & Safety in the Treatment of Opioid Addiction. Addiction Treatment Forum. Available at: http:\/\/www.atforum.com\/pdf\/DosingandSafetyWP.pdf (accessed 19 Jun 2013)."},{"key":"bibr41-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2007.10.017"},{"key":"bibr42-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1126\/science.278.5335.45"},{"key":"bibr43-0269881114555248","unstructured":"Lintzeris N, Clark N, Winstock A, (2006) National Clinical Guidelines and Procedures for the Use of Buprenorphine in the Treatment of Opioid Dependence. www.health.gov.au. Available at: www.health.gov.au\/internet\/drugstrategy\/publishing.nsf\/Content\/buprenorphine-guide (accessed 14 Feb 2011)."},{"issue":"1","key":"bibr44-0269881114555248","first-page":"49","volume":"23","author":"Lintzeris N","year":"2001","journal-title":"Research and Clinical Forums"},{"key":"bibr45-0269881114555248","doi-asserted-by":"publisher","DOI":"10.3109\/00952999209026068"},{"key":"bibr46-0269881114555248","unstructured":"Magura S, Rosenblum A (2001) Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored. Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored MT SINAI J Pfizer MEDICINE 68: 62\u201374 (PMID:11135508)"},{"key":"bibr47-0269881114555248","doi-asserted-by":"publisher","DOI":"10.2174\/1874473711205010052"},{"key":"bibr48-0269881114555248","doi-asserted-by":"publisher","DOI":"10.2147\/SAR.S15853"},{"issue":"2","key":"bibr49-0269881114555248","first-page":"5","volume":"13","author":"Maremmani I","year":"2011","journal-title":"Heroin Addict Relat Clin Probl"},{"issue":"4","key":"bibr50-0269881114555248","first-page":"19","volume":"10","author":"Maremmani I","year":"2008","journal-title":"Heroin Addict Relat Clin Probl"},{"key":"bibr51-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2006.11.009"},{"key":"bibr52-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1086\/429503"},{"key":"bibr53-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(03)00057-7"},{"key":"bibr54-0269881114555248","unstructured":"National Treatment Agency for Substance Misuse (2006) Models of Care for Treatment of Adult Drug Misusers. http:\/\/www.nta.nhs.uk. Available at: http:\/\/www.nta.nhs.uk\/uploads\/nta_modelsofcare_update_2006_moc3.pdf (accessed 19 Jun 2013)."},{"key":"bibr55-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1111\/jep.12045"},{"key":"bibr56-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1177\/0269881109356129"},{"key":"bibr57-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.07.013"},{"key":"bibr58-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(00)00163-0"},{"key":"bibr59-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2010.07.009"},{"key":"bibr60-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2005.11.008"},{"key":"bibr61-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1037\/0033-2909.117.3.416"},{"key":"bibr62-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1080\/00952990701523698"},{"key":"bibr63-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1177\/0193841X9802200202"},{"key":"bibr64-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2011.12.008"},{"key":"bibr65-0269881114555248","unstructured":"SAMHSA (2009) Guiding Principles and Elements of Recovery-Oriented Systems of Care: What do we know from the research? www.samhsa.gov (accessed 2 Aug 2012)."},{"key":"bibr66-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2010.531670"},{"key":"bibr67-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(99)00104-0"},{"key":"bibr68-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1497.2005.0228.x"},{"key":"bibr69-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199206000-00010"},{"key":"bibr70-0269881114555248","unstructured":"Strang J (2012) Medications in recovery re-orientating drug dependence treatment. Accessed on 25 February 2012 from: www.nta.nhs.uk\/medications-in-recovery-main-report.aspx."},{"key":"bibr71-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2011.03515.x"},{"key":"bibr72-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(03)00056-5"},{"key":"bibr73-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.71"},{"key":"bibr74-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2004.10400047"},{"key":"bibr75-0269881114555248","unstructured":"WHO UNODC UNAIDS (2004) WHO\/UNODC\/UNAIDS position paper: Substitution maintenance therapy in the management of opioid dependence and HIV\/AIDS prevention. www.who.int. Available at: www.who.int\/substance_abuse\/publications\/treatment\/en\/index.html (accessed 19 Jun 2013)."},{"key":"bibr76-0269881114555248","unstructured":"World Health Organization (2009) Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. www.who.int. Available at: www.who.int\/substance_abuse\/publications\/treatment\/en\/index.html (accessed 19 Jun 2013)."},{"key":"bibr77-0269881114555248","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2000.951778.x"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881114555248","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0269881114555248","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881114555248","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:08:17Z","timestamp":1777507697000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0269881114555248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,11]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1177\/0269881114555248"],"URL":"https:\/\/doi.org\/10.1177\/0269881114555248","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,11]]}}}